{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T08:38:16Z","timestamp":1792658296864,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ahj.2015.11.015","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T19:24:37Z","timestamp":1450466677000},"page":"94-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":158,"special_numbering":"C","title":["Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial"],"prefix":"10.1016","volume":"173","clinical-trial-number":[{"clinical-trial-number":"nct01764633","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Marc S.","family":"Sabatine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Giugliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Keech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narimon","family":"Honarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M.","family":"Wasserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter S.","family":"Sever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terje R.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2015.11.015_bb0005","series-title":"World health statistics 2015","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.ahj.2015.11.015_bb0010","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists C","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.11.015_bb0015","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"Coronary Drug Project Research Group","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2015.11.015_bb0020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jama.1984.03340270029025","article-title":"The lipid research clinics coronary primary prevention trial results","volume":"251","author":"Lipid Research Clinics Program","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2015.11.015_bb0025","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.11.015_bb0030","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.11.015_bb0035","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.11.015_bb0040","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0092-8674(83)90052-1","article-title":"Recycling receptors: the round-trip itinerary of migrant membrane proteins","volume":"32","author":"Brown","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.ahj.2015.11.015_bb0045","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are pcsk9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.11.015_bb0050","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.11.015_bb0055","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.11.015_bb0060","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1001\/jama.2014.4030","article-title":"Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial","volume":"311","author":"Robinson","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2015.11.015_bb0065","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.11.015_bb0070","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.11.015_bb0075","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","article-title":"PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial","volume":"385","author":"Raal","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.11.015_bb0080","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/eurheartj\/ehu085","article-title":"Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials","volume":"35","author":"Stein","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2015.11.015_bb0085","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"issue":"Suppl","key":"10.1016\/j.ahj.2015.11.015_bb0090","doi-asserted-by":"crossref","first-page":"A1368","DOI":"10.1016\/S0735-1097(15)61368-7","article-title":"Clinical equivalence of evolocumab 140 mg every two weeks and 420 mg monthly dosing regimens: a pooled analysis of 3146 patients in phase 3 studies","volume":"65","author":"Stein","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.11.015_bb0095","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/CIR.0000000000000156","volume":"132","author":"Hicks","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2015.11.015_bb0100","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc B"},{"key":"10.1016\/j.ahj.2015.11.015_bb0105","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0197-2456(95)00132-8","article-title":"Sample size calculation for complex clinical trials with survival endpoints","volume":"16","author":"Shih","year":"1995","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.ahj.2015.11.015_bb0110","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF02244644","article-title":"Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB","volume":"110","author":"Sahakian","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ahj.2015.11.015_bb0115","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.pnpbp.2007.01.011","article-title":"Automated neuropsychological test battery (CANTAB) in mild cognitive impairment and in Alzheimer's disease","volume":"31","author":"Egerhazi","year":"2007","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.ahj.2015.11.015_bb0120","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jacc.2005.05.085","article-title":"Pleiotropic effects of statins: benefit beyond cholesterol reduction? A meta-regression analysis","volume":"46","author":"Robinson","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.11.015_bb0125","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1056\/NEJMc0707445","article-title":"A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.11.015_bb0130","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.11.015_bb0135","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2015.11.015_bb0140","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.ahj.2015.11.015_bb0145","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1016\/S0735-1097(15)60004-3","article-title":"Baseline LDL-C and clinical outcomes with addition of ezetimibe to statin in 18,144 patients post ACS","volume":"65","author":"Giugliano","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2015.11.015_bb0150","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCRESAHA.115.306493","article-title":"PCSK9 inhibition to lower LDL-cholesterol and reduce cardiovascular risk: great expectations","volume":"116","author":"Waters","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2015.11.015_bb0155","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2015.11.015_bb0160","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.ahj.2015.11.015_bb0165","first-page":"2","article-title":"Safety and efficacy of long-term very low achieved LDL-C in the IMPROVE-IT trial","volume":"36","author":"Giugliano","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2015.11.015_bb0170","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.11.015_bb0175","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(14)61183-1","article-title":"HMG-coenzyme a reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials","volume":"385","author":"Swerdlow","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.11.015_bb0180","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1001\/jama.2015.1206","article-title":"Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus","volume":"313","author":"Besseling","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2015.11.015_bb0185","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2015.11.015_bb0190","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00415-009-5271-7","article-title":"Pravastatin and cognitive function in the elderly. Results of the prosper study","volume":"257","author":"Trompet","year":"2010","journal-title":"J Neurol"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315006869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870315006869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T05:55:25Z","timestamp":1757570125000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870315006869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":38,"alternative-id":["S0002870315006869"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2015.11.015","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2015.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}